BLRX vs. RVPH, BOLT, RMTI, CLNN, RPHM, EQ, IMRX, CKPT, AADI, and KZR
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Reviva Pharmaceuticals (RVPH), Bolt Biotherapeutics (BOLT), Rockwell Medical (RMTI), Clene (CLNN), Reneo Pharmaceuticals (RPHM), Equillium (EQ), Immuneering (IMRX), Checkpoint Therapeutics (CKPT), Aadi Bioscience (AADI), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical preparations" industry.
BioLineRx (NASDAQ:BLRX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.
BioLineRx's return on equity of -280.21% beat Reviva Pharmaceuticals' return on equity.
In the previous week, Reviva Pharmaceuticals had 9 more articles in the media than BioLineRx. MarketBeat recorded 10 mentions for Reviva Pharmaceuticals and 1 mentions for BioLineRx. Reviva Pharmaceuticals' average media sentiment score of 0.83 beat BioLineRx's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.
Reviva Pharmaceuticals has lower revenue, but higher earnings than BioLineRx. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
BioLineRx has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.
BioLineRx received 487 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.89% of users gave Reviva Pharmaceuticals an outperform vote while only 73.32% of users gave BioLineRx an outperform vote.
1.6% of BioLineRx shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
BioLineRx presently has a consensus price target of $21.00, suggesting a potential upside of 3,181.25%. Reviva Pharmaceuticals has a consensus price target of $16.33, suggesting a potential upside of 878.04%. Given BioLineRx's higher possible upside, research analysts plainly believe BioLineRx is more favorable than Reviva Pharmaceuticals.
Summary
BioLineRx beats Reviva Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
